Molecular pathways: targeting the dependence of mutant RAS cancers on the DNA damage response

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• RAS mutations are common in cancer but remain challenging therapeutic targets.
• RAS-driven cancers exhibit dependencies on non-oncogenic signaling pathways for survival.
• These dependencies represent unique vulnerabilities exploitable for cancer treatment.

Purpose of the Study:

• To review the dependence of RAS-mutant cancers on the DNA damage response (DDR).
• To discuss molecular pathways mediating this DDR dependence, including wild-type Ras signaling, ATR/Chk1, and DNA repair.
• To explore therapeutic strategies combining chemotherapy with targeted inhibition of these pathways.

Main Methods:

• Literature review of studies on RAS biology and cancer dependencies.
• Analysis of molecular pathways involved in RAS-driven tumorigenesis and DDR.
• Discussion of potential therapeutic interventions targeting identified vulnerabilities.

Main Results:

• RAS-mutant cells rely on specific signaling pathways, including the DNA damage response, for adaptation and survival.
• Key mediators of this dependence include wild-type Ras isoforms, ATR/Chk1 signaling, and DNA repair mechanisms.
• These findings highlight vulnerabilities in RAS-driven cancers.

Conclusions:

• RAS-mutant cancers exhibit a critical dependence on the DNA damage response.
• Combinatorial therapies involving DNA-damaging agents and inhibitors of wild-type Ras signaling, ATR/Chk1, or DNA repair pathways are promising.
• Targeting these dependencies offers a potential therapeutic avenue for RAS-driven cancers.